Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday, September 18th.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 9th. Piper Jaffray Companies started coverage on shares of Catalyst Pharmaceuticals in a research report on Friday, September 7th. They issued an “overweight” rating and a $5.00 price objective on the stock. ValuEngine lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. Oppenheimer set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Monday, August 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Catalyst Pharmaceuticals has a consensus rating of “Hold” and an average target price of $5.61.

CPRX traded up $0.05 during trading on Tuesday, hitting $3.14. The stock had a trading volume of 1,273,532 shares, compared to its average volume of 684,830. The stock has a market capitalization of $387.83 million, a P/E ratio of -14.95 and a beta of 1.46. Catalyst Pharmaceuticals has a twelve month low of $2.18 and a twelve month high of $4.51.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, sell-side analysts anticipate that Catalyst Pharmaceuticals will post -0.29 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of CPRX. Lido Advisors LLC acquired a new stake in Catalyst Pharmaceuticals during the 1st quarter worth approximately $142,000. MetLife Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the second quarter valued at approximately $157,000. New York State Common Retirement Fund grew its position in Catalyst Pharmaceuticals by 47.6% in the first quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 24,200 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Catalyst Pharmaceuticals in the first quarter valued at approximately $230,000. Finally, Rhumbline Advisers grew its position in Catalyst Pharmaceuticals by 34.7% in the second quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 23,383 shares in the last quarter. 51.49% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Read More: Why do company’s buyback their stock?

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.